Botulinum Toxin for the Treatment of Focal Task-Specific Hand Dystonias: Systematic Review and Meta-Analysis
| Autor: | Maria C. Tan, Christine Guptill, Nigel L. Ashworth, Alexander Doroshenko, Sebastian Straube, David M. Antle, Douglas P. Gross, Charl Els, Henry Aidoo, Patrick J. Potter, David Mark Flaschner |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Dystonia medicine.medical_specialty business.industry medicine.disease Botulinum toxin Task (project management) Clinical trial 03 medical and health sciences Psychiatry and Mental health 030104 developmental biology 0302 clinical medicine Physical medicine and rehabilitation Neurology Meta-analysis medicine Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | The Open Neurology Journal. 13:32-44 |
| ISSN: | 1874-205X |
| DOI: | 10.2174/1874205x01913010032 |
| Popis: | Objective:Botulinum Toxin (BTX) has become a widely used treatment in several dystonic conditions, but the evidence for its efficacy has largely come from open trials and expert opinion. This systematic review examined the efficacy and safety of BTX in the treatment of Focal Hand Dystonia (FHD) in Randomized Controlled Trials (RCTs).Methods:We searched Ovid MEDLINE, EMBASE, Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE), Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, SPORT Discus, SCOPUS, Web of Science, PEDro, ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) for randomized, placebo-controlled trials on the use of BTX for FHD.Results:Of 1,116 publications retrieved from the databases searched, three publications were included. The evidence identified pertains to focal task-specific hand dystonias. Sixty-nine participants were involved in the three RCTs with a mean duration of symptoms of 7.5 years. Participants were assessed using a combination of self-reported and functional performance outcome measures following injections of BTX subtype A (BTX-A) or placebo. The Oxford Quality Scale was used to assess the included studies, and the three studies each scored 3/5 or above. The included studies reported no adverse events with BTX-A use, other than muscle weakness and pain at the injection sites.Conclusion:The number of participants included in these three trials is too small to draw dependable conclusions about the efficacy and safety of BTX-A for FHD. There is currently not enough evidence to recommend the routine use of BTX-A for FHD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|